Tactile Medical Grows Despite Minor Setbacks | Business and Finance News

Tactile Medical’s Q2 earnings show strong lymphedema growth—up 12% YoY to $73M—while AffloVest dips slightly due to partner inventory shifts, but remains up 32% over the past year. Profitability is soaring: gross margins jumped 180 bps, adjusted EBITDA hit $11.4M, and cash reserves sit at $70M for reinvestment. They’ve raised full-year revenue guidance to $360–366M and inked a key DOD deal to distribute MyoSleeve to veterans. Focused on three pillars—access, expansion, and patient value—they’re backing new clinical data for Flexitouch and pushing for expanded LymphaTech diagnostics. With strategic moves and solid fundamentals, Tactile Medical is poised for sustainable, profitable growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6055bdf93a33ea6a